New hope for advanced bladder cancer: testing Triple-Drug combos
NCT ID NCT05845814
Summary
This study is testing whether adding new experimental drugs to a standard two-drug treatment works better for people with advanced bladder cancer that has spread. It will involve about 390 participants who have not yet received treatment for their advanced cancer. The main goals are to see if the new combinations shrink tumors more effectively and are safe enough for patients to tolerate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anschutz Cancer Pavilion ( Site 3017)
Aurora, Colorado, 80045, United States
-
Asan Medical Center-Department of Oncology ( Site 3901)
Seoul, 05505, South Korea
-
Austin Health-Cancer Clinical Trials Centre ( Site 3950)
Heidelberg, Victoria, 3084, Australia
-
Bradford Hill Norte ( Site 3152)
Antofagasta, 1240000, Chile
-
Bradfordhill-Clinical Area ( Site 3155)
Santiago, Region M. de Santiago, 8420383, Chile
-
CHU de Bordeaux Hop St ANDRE ( Site 3607)
Bordeaux, Aquitaine, 33075, France
-
Centre Georges François Leclerc-Centre de recherche clinique ( Site 3608)
Dijon, Cote-d Or, 21079, France
-
Chang Gung Memorial Hospital at Kaohsiung-Oncology and Hematology ( Site 3802)
Kaohsiung City, 83301, Taiwan
-
Cleveland Clinic-Taussig Cancer Center ( Site 3036)
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute ( Site 3047)
Boston, Massachusetts, 02115, United States
-
Duke Cancer Institute ( Site 3027)
Durham, North Carolina, 27710, United States
-
Emory University School of Medicine ( Site 3043)
Atlanta, Georgia, 30322, United States
-
Erasmus Medisch Centrum-Medical Oncology ( Site 3303)
Rotterdam, South Holland, 3015 GD, Netherlands
-
FALP-UIDO ( Site 3151)
Santiago, Region M. de Santiago, 7500921, Chile
-
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 3405)
Milan, Lombardy, 20133, Italy
-
Hospital Clinico San Carlos ( Site 3765)
Madrid, 28040, Spain
-
Hospital Universitari Vall d'Hebron ( Site 3767)
Barcelona, Catalonia, 08035, Spain
-
Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 3041)
Salt Lake City, Utah, 84112, United States
-
Hôpital Européen Georges Pompidou ( Site 3605)
Paris, 75015, France
-
Icahn School of Medicine at Mount Sinai ( Site 3018)
New York, New York, 10029, United States
-
Indiana University Melvin and Bren Simon Cancer Center ( Site 3011)
Indianapolis, Indiana, 46202, United States
-
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 3406)
Napoli, Campania, 80131, Italy
-
Maastricht UMC+ ( Site 3304)
Maastricht, Limburg, 6229 HX, Netherlands
-
Memorial Sloan Kettering Cancer Center ( Site 3031)
New York, New York, 10065, United States
-
Moores Cancer Center ( Site 3028)
La Jolla, California, 92093-0698, United States
-
National Cheng Kung University Hospital-Clinical Trial Center ( Site 3803)
Tainan, 704, Taiwan
-
National Taiwan University Hospital-Oncology ( Site 3801)
Taipei, 10002, Taiwan
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 3302)
Amsterdam, North Holland, 1066 CX, Netherlands
-
ONCOCENTRO APYS-ACEREY ( Site 3158)
Viña del Mar, Región de Valparaíso, 2520598, Chile
-
Oncopole Claudius Regaud ( Site 3610)
Toulouse, Haute-Garonne, 31059, France
-
Ospedale San Raffaele-Oncologia Medica ( Site 3403)
Milan, 20132, Italy
-
Princess Margaret Cancer Centre ( Site 3106)
Toronto, Ontario, M5G 2M9, Canada
-
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 3201)
London, London, City of, SW3 6JJ, United Kingdom
-
Rabin Medical Center-Oncology ( Site 3504)
Petah Tikva, 4941492, Israel
-
Rambam Health Care Campus-Oncology Division ( Site 3501)
Haifa, 3109601, Israel
-
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 3951)
Brisbane, Queensland, 4029, Australia
-
Samsung Medical Center ( Site 3902)
Seoul, 06351, South Korea
-
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3903)
Seoul, 03722, South Korea
-
Sheba Medical Center-ONCOLOGY ( Site 3503)
Ramat Gan, 5265601, Israel
-
Siteman Cancer Center ( Site 3038)
St Louis, Missouri, 63108, United States
-
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 3206)
London, London, City of, EC1A 7BE, United Kingdom
-
Sunnybrook Research Institute - Odette Cancer Centre ( Site 3108)
Toronto, Ontario, M4N 3M5, Canada
-
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 3105)
Ottawa, Ontario, K1H 8L6, Canada
-
UCSF Medical Center at Mission Bay ( Site 3044)
San Francisco, California, 94158, United States
-
UPMC Hillman Cancer Center ( Site 3014)
Pittsburgh, Pennsylvania, 15232, United States
-
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3045)
Orange, California, 92868, United States
-
centre hospitalier lyon sud ( Site 3606)
Pierre-Bénite, Rhone, 69310, France
Conditions
Explore the condition pages connected to this study.